×

Liquid formulations for proteinic pharmaceuticals

  • US 5,653,987 A
  • Filed: 05/16/1995
  • Issued: 08/05/1997
  • Est. Priority Date: 05/16/1995
  • Status: Expired due to Term
First Claim
Patent Images

1. A liquid pharmaceutical agent formulation suitable for oral or nasal delivery comprising a proteinic pharmaceutical agent, water and at least two absorption enhancing compounds, wherein said absorption enhancing compounds are selected from the group consisting of a combination of deoxycholate, chenodeoxycholate, and polyoxyethylene 9-lauryl ether, a combination of sodium salicylate, deoxycholate, chenodeoxycholate, and polyoxyethylene 9-lauryl ether, a combination of sodium deoxycholate, chenodeoxycholate, polyoxyethylene 9-lauryl ether and monoolein, a combination of deoxycholate, chenodeoxycholate and sodium salicylate, a combination of deoxycholate, sodium salicylate and sodium lauryl sulphate, a combination of oleic acid, linoleic acid and sodium lauryl sulphate, a combination of monoolein, deoxycholate and polyoxyethylene 9-lauryl ether, a combination of deoxycholate, chenodeoxycholate, polyoxyethylene 9-lauryl ether and sodium tauro-24, 25-dihydrofusidate, a combination of sodium deoxycholate, chenodeoxycholate, polyoxyethylene 9-lauryl ether and sodium tauro-24, 25-dihydrofusidate, a combination of deoxycholate, chenodeoxycholate, taurodeoxycholate, polyoxyethylene 9-lauryl ether and monoolein, a combination of chenodeoxycholate, glycochenodeoxycholate, polyoxyethylene 9-lauryl ether and sodium tauro-24, 25-dihydrofusidate, a combination of chenodeoxycholate, sodium lauryl sulphate and disodium EDTA, a combination of deoxycholate, chenodeoxycholate, polyoxyethylene 9-lauryl ether and disodium EDTA, a combination of sodium salicylate, disodium EDTA and polyoxyethylene 9-lauryl ether, a combination of monoolein, oleic acid and polyoxyethylene sorbitan ester, a combination of monoolein, oleic acid, polyoxyethylene sorbitan ester and sodium lauryl sulphate, and a combination of linoleic acid, monoolein and sodium salicylate, wherein the amount of each of the absorption enhancing compounds is present in a concentration of from 1 to 10 wt./wt. % of the total formulation.

View all claims
  • 0 Assignments
Timeline View
Assignment View
    ×
    ×